UBS Group’s Orion Biotech Opportunities Corp. Warrant ORIAW Stock Holding History

UBS Group’s Portfolio ORIAW Stock Details ORIAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5	Closed	–	–	10359
2023 Q1	$0	Sell	5 -891	-99%	-$232	﹤0.01%	11189
2022 Q4	$134	Sell	896 -1	-0.1%	–	﹤0.01%	10363
2022 Q3	$0	Buy	+897	New	+$194	﹤0.01%	11423
2022 Q2	–	Sell	-495	Closed	–	–	11407
2022 Q1	$0	Buy	+495	New	+$255	﹤0.01%	11290

UBS Group's ORIAW Position: Q2 2023 in Review

UBS Group sold out of Orion Biotech Opportunities Corp. Warrant (ORIAW) in Q2 2023, closing a stake of 5 shares.

UBS Group first reported a position in ORIAW in Q1 2022 and held it in 4 quarters. The position peaked at $134 in Q4 2022. 0 funds tracked by Wall St. Rank hold ORIAW as of Q2 2023.

UBS Group reported no remaining Orion Biotech Opportunities Corp. Warrant position as of Q2 2023 after selling out during the quarter.
UBS Group sold 5 Orion Biotech Opportunities Corp. Warrant shares in Q2 2023.
UBS Group first reported a position in Orion Biotech Opportunities Corp. Warrant in Q1 2022 and held it in 4 quarters.
UBS Group's Orion Biotech Opportunities Corp. Warrant position peaked at $134 in Q4 2022.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Warrant as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.